Moberg Pharma AB Year-end report January - June 2019
EXECUTING ACCORDING TO PLAN WITH FOCUS ON MOB-015PERIOD (JAN-JUN 2019) · Net profit after tax SEK 558.8 million (6.7) · Total profit for the period SEK 499.4 million (27.3) · Diluted earnings per share SEK 31.35 (0.38) · Net revenue SEK 15.6 million (0.0) * · EBITDA SEK -3.0 million (-21.0) * · Operating profit (EBIT) SEK -4.2 million (-21.1) * · Cash and cash equivalents amounted to SEK 919.1 million (122.2) SECOND QUARTER (APR-JUN 2019) · Net profit after tax SEK -5.1 million (4.7) · Total profit for the period SEK -5.1 million (21.7) · Diluted